- Home
- GAM vs TRVI Comparison
GAM vs TRVI Comparison
Compare GAM & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAM
- TRVI
- Stock Information
- Founded
- GAM 1927
- TRVI 2011
- Country
- GAM United States
- TRVI United States
- Employees
- GAM N/A
- TRVI N/A
- Industry
- GAM Investment Managers
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- GAM Finance
- TRVI Health Care
- Exchange
- GAM Nasdaq
- TRVI Nasdaq
- Market Cap
- GAM 1.3B
- TRVI 1.4B
- IPO Year
- GAM N/A
- TRVI 2019
- Fundamental
- Price
- GAM $57.16
- TRVI $11.03
- Analyst Decision
- GAM
- TRVI Strong Buy
- Analyst Count
- GAM 0
- TRVI 11
- Target Price
- GAM N/A
- TRVI $20.59
- AVG Volume (30 Days)
- GAM 20.1K
- TRVI 1.5M
- Earning Date
- GAM 01-01-0001
- TRVI 11-13-2025
- Dividend Yield
- GAM 5.74%
- TRVI N/A
- EPS Growth
- GAM N/A
- TRVI N/A
- EPS
- GAM 11.67
- TRVI N/A
- Revenue
- GAM N/A
- TRVI N/A
- Revenue This Year
- GAM N/A
- TRVI N/A
- Revenue Next Year
- GAM N/A
- TRVI N/A
- P/E Ratio
- GAM $3.95
- TRVI N/A
- Revenue Growth
- GAM N/A
- TRVI N/A
- 52 Week Low
- GAM $37.32
- TRVI $2.36
- 52 Week High
- GAM $46.48
- TRVI $12.30
- Technical
- Relative Strength Index (RSI)
- GAM 23.84
- TRVI 52.22
- Support Level
- GAM $56.24
- TRVI $11.15
- Resistance Level
- GAM $58.22
- TRVI $12.14
- Average True Range (ATR)
- GAM 0.97
- TRVI 0.66
- MACD
- GAM -0.83
- TRVI -0.13
- Stochastic Oscillator
- GAM 8.58
- TRVI 38.03
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.